A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Autor: C. Delcambre, C. Guillemet, Raissa Kapso, A. Fraslin, Sophie Piperno-Neumann, Sébastien Salas, L. Haddag, Loic Chaigneau, N. Bouvet, Emmanuelle Bompas, Antoine Italiano, François Bertucci, Julia Bonastre, Maria Rios, Jacques-Olivier Bay, Stéphanie Foulon, Didier Cupissol, Christine Chevreau, Nicolas Penel, Olivier Mir, N. Isambert, A. Le Cesne, J.-Y. Blay, I.L. Ray-Coquard

Publikováno v: Annals of Oncology. 32:1034-1044

The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS).This randomized, multicenter, open-label, phase III study included

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cccbc01935ea2f259c2662d84bc2879a
https://doi.org/10.1016/j.annonc.2021.04.014

LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

Autor: M. Sundqvist, Nicolas Penel, C. Balleyguier, Emmanuelle Bompas, Maria Rios, Christine Chevreau, C. Delcambre, Patricia Pautier, Sophie Piperno-Neumann, P. Boudou Rouquette, N. Isambert, Olivier Collard, Florence Duffaud, Valerie Lebrun-Ly, Elsa Kalbacher, J-Y. Blay, C. Guillemet, Didier Cupissol, Antoine Italiano, François Bertucci

Publikováno v: Annals of Oncology. 32:S1335-S1336

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b53eb991933214cef9840a7d8c418b1
https://doi.org/10.1016/j.annonc.2021.08.2139

Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Autor: Johannes H.A.M. Kaanders, Dominique Ranchère-Vince, B. De Bari, J.-Y. Blay, H.F. Dincbas, Salvador Villà, Corinne Bouvier, S. Bonvalot, Thomas Zilli, S. Torrente, N. Resseguier, Jacob Habboush, Florence Duffaud, P. Terrier, K. Khanfir, N. Isambert, Tatiana Dragan, A. Le Cesne, Nicolas Macagno, P. Dubray-Longeras, C. Delcambre, Gamze Ugurluer, C. Lemoine, Antoine Italiano, François Bertucci, Patrick Soulié, Didier Cupissol, Sébastien Salas, David Pasquier, L. Myroslav, Philippe Rosset, Claudio V. Sole, Nicolas Penel, J.-M. Coindre, Marick Laé, Juliette Thariat, Tiziana Cena, Marco Krengli, Jacques-Olivier Bay, Christine Chevreau

Publikováno v: Annals of Oncology, 28, 1979-1987
Annals of Oncology
Annals of Oncology, Elsevier, 2017, 28 (8), pp.1979-1987. ⟨10.1093/annonc/mdx250⟩
Annals of Oncology, 28, 8, pp. 1979-1987
Annals of Oncology, 2017, 28 (8), pp.1979-1987. ⟨10.1093/annonc/mdx250⟩

Item does not contain fulltext Background: Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors. Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e7e7f9cb3af2e0d4eb43891c24cb2b
https://hdl.handle.net/2066/177897

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Autor: Corinne Bouvier, Valérie Laurence, Mathilde Cancel, Vincent Vidal, Olivier Mir, L. Monard, Christophe Perrin, P. Boudou Rouquette, C. Schiffler, Sylvie Chabaud, Emmanuelle Bompas, François Bertucci, Florence Duffaud, Christine Chevreau, Nicolas Penel, Nathalie Gaspar, Esma Saada-Bouzid, C. Delcambre, J-Y. Blay, Elsa Kalbacher

Publikováno v: Annals of Oncology. 31:S1199

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2fccd49a508946ee4b9deeabf0f6834
https://doi.org/10.1016/j.annonc.2020.08.2309

How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study

Autor: Florence Joly, C. Delcambre, Audrey Faveyrial, Elodie Coquan, Sophie Gouérant, M.P. Galais, Katharina Gunzer, Laure Kaluzinski, Emmanuel Sevin, Florence Polycarpe, Gilles Saucier, Julie Vanbockstael, Ioana Hrab, Radj Gervais, A.-C. Lefebvre, Michel André, Bénédicte Clarisse, Jean-Michel Grellard, J.F. Héron, D. Allouache, Sabine Noal, Brigitte Vie, Noëmie Lemenand, Audrey Emmanuelle Dugué

Publikováno v: Supportive Care in Cancer. 24:1131-1138

Chemotherapy-induced nausea and vomiting (CINV) still remain frequent. The procedure for announcing the diagnosis (PAD) was an emblematic measure of the first French Plan Cancer aiming at providing patients with time to listen, information after canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586d98fc482c48f8e58b3276c38b5153
https://doi.org/10.1007/s00520-015-2882-7